Behaviors and Persistence of Nanomaterials in Biomedical Applications

Index

A

• Amphiphilic, 24, 26, 32–34, 185
• Anisotropic, 40–42, 45, 49, 51, 52, 56, 60, 63, 72, 74–76, 86,93,147, 182, 186, 220
• Anisotropy, 18, 19, 53, 55, 58, 75, 109, 131
• Atomic orbitals, 16
• Azeotrope, 28

B

• Biocompatibility, 13, 22, 34, 36, 59, 65, 68, 69, 103, 134, 150, 190, 197, 222, 228, 232
• Biocompatible, 24, 31, 33, 38, 59, 77, 83, 133, 197, 223, 229
• Biodegradable, 33, 70, 103, 176, 179, 180, 191, 218, 221, 223, 225, 234, 235, 244
• Blood vessels, 162
• Bulk, 5–12, 14, 16–18, 20, 22, 64, 66

C

• C60 fullerene, 22
• Carbohydrates, 32, 33, 95
• Carbon dots, 14, 15, 23, 62, 64, 68, 77, 106, 133, 150, 180, 181, 188, 198, 199, 210, 211, 215
• Carbon nanodiamonds, 23
• Carbon nanomaterials, 22–25, 67, 188
• Carbon nanotubes, 22, 68, 69, 77, 86, 109, 117, 129, 169,180, 182, 188, 191, 199, 210, 215
• Carbonaceous nanomaterials, 23, 25
• Caveolae, 140–142, 145, 183–185
• Cell penetrating peptides, 144
• Chemotherapeutics, 101, 140, 162, 202, 205, 225
• Chemotherapy, 70, 99, 100, 101, 103, 111, 112, 123–126, 128, 131, 132, 140, 184, 194, 195, 208, 209
• Chitosan, 32–34, 70, 107, 148, 176, 187, 198
• Cisplatin, 34, 70, 100, 102–105, 123–125, 164, 194, 206, 235
• Clathrin, 138–141, 146, 183, 199
• Clearance, 82, 125, 138, 156–158, 164, 172, 176, 178–182, 191, 194, 197–199, 221–223, 230, 234, 244
• Clinical translation, 202, 206, 209, 212, 215, 217, 218, 225, 233, 243
• Clusters, 12, 13, 66, 67, 116, 182,222, 228, 234, 236
• CNTs, 22–24
• Colloidal metal, 39
• Compton scattering, 80
• Copaxone, 208
• Crosslinkers, 32
• Cu NPs, ...